Cargando…

Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials

Arterial and venous thrombotic events in COVID-19 cause significant morbidity and mortality among patients. Although international guidelines agree on the need for anticoagulation, it is unclear whether full-dose heparin anticoagulation confers additional benefits over prophylactic-dose anticoagulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pilia, Eros, Belletti, Alessandro, Fresilli, Stefano, Finco, Gabriele, Landoni, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362611/ https://www.ncbi.nlm.nih.gov/pubmed/35922578 http://dx.doi.org/10.1007/s11239-022-02681-x

Ejemplares similares

The Effect of Heparin Full-Dose Anticoagulation on Survival of Hospitalized, Non-critically Ill COVID-19 Patients: A Meta-analysis of High Quality Studies
por: Pilia, Eros, et al.
Publicado: (2023)

Anticoagulation Strategies in Critically Ill Patients With SARS-CoV-2 Infection: The Role of Direct Thrombin Inhibitors
por: Pieri, Marina, et al.
Publicado: (2022)

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Publicado: (2021)

CRITICALLY ILL COVID-19 PATIENTS AND THERAPEUTIC ANTICOAGULATION WITH HEPARIN
por: Vu, Michael, et al.
Publicado: (2022)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Bivalirudin or heparin: which anticoagulation strategy for critically ill cardiac surgery patients?
por: Pappalardo, F, et al.
Publicado: (2014)

P-SILI in critically ill COVID-19 patients: Macklin effect and the choice of noninvasive ventilatory support type
por: Belletti, Alessandro, et al.
Publicado: (2023)

Regional Anticoagulation with Citrate is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
por: Park, Joon-Sung, et al.
Publicado: (2011)

Positive single-center randomized trials and subsequent multicenter randomized trials in critically ill patients: a systematic review
por: Kotani, Yuki, et al.
Publicado: (2023)

Continuation of therapeutic dose heparin for critically ill patients with COVID-19
por: Bradbury, Charlotte A., et al.
Publicado: (2023)

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Publicado: (2021)

Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients a systematic review and meta-analysis of randomized controlled trials
por: Bonfim, Luana C.M.G., et al.
Publicado: (2023)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
por: Paez Vargas, Juan José, et al.
Publicado: (2021)

Dexmedetomidine as a Sedative Agent in Critically Ill Patients: A Meta-Analysis of Randomized Controlled Trials
por: Pasin, Laura, et al.
Publicado: (2013)

Correction: Dexmedetomidine as a Sedative Agent in Critically Ill Patients: A Meta-Analysis of Randomized Controlled Trials
por: Pasin, Laura, et al.
Publicado: (2014)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Pneumothorax and barotrauma in invasively ventilated patients with COVID-19
por: Belletti, Alessandro, et al.
Publicado: (2021)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Outcome of cardiac surgery in patients with low preoperative ejection fraction
por: Pieri, Marina, et al.
Publicado: (2016)

Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
por: Zuily, Stéphane, et al.
Publicado: (2023)

The Effect of Statins on Mortality in Septic Patients: A Meta-Analysis of Randomized Controlled Trials
por: Pasin, Laura, et al.
Publicado: (2013)

Early prophylactic anticoagulation with heparin alleviates mortality in critically ill patients with sepsis: a retrospective analysis from the MIMIC-IV database
por: Zou, Zhi-ye, et al.
Publicado: (2022)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Engineered heparins as new anticoagulant drugs
por: Vaidyanathan, Deepika, et al.
Publicado: (2016)

Non-Anticoagulant Heparins as Heparanase Inhibitors
por: Cassinelli, Giuseppe, et al.
Publicado: (2020)

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
por: Tacquard, Charles, et al.
Publicado: (2021)

Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia
por: Nilius, Henning, et al.
Publicado: (2021)

Effectiveness of thromboprophylaxis with low molecular weight heparin in critically ill patients with COVID-19. An observational prospective, multicenter study
por: Ferrandis, R., et al.
Publicado: (2023)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

Heparin requirements for full anticoagulation are higher for patients on dabigatran than for those on warfarin – a model-based study
por: Edrich, Thomas, et al.
Publicado: (2015)

The standard of care is standard for a reason: Commentary on “Optimal dosing of heparin for prophylactic anticoagulation in critically ill COVID-19 patients: A systematic review and Meta-analysis of randomized clinical trials”
por: Milano, Victoria, et al.
Publicado: (2023)

Non-Adrenergic Vasopressors in Patients with or at Risk for Vasodilatory Shock. A Systematic Review and Meta-Analysis of Randomized Trials
por: Belletti, Alessandro, et al.
Publicado: (2015)

Full versus prophylactic-intermediate doses of anticoagulants in COVID-19: a meta-analysis
por: Loffredo, Lorenzo, et al.
Publicado: (2022)

Response to: norepinephrine formulation for equivalent vasopressive score
por: Kotani, Yuki, et al.
Publicado: (2023)

Citrate Anticoagulation for CRRT in Children: Comparison with Heparin
por: Fernández, Sara Nicole, et al.
Publicado: (2014)

Heparin and Related Drugs: Beyond Anticoagulant Activity
por: Page, Clive
Publicado: (2013)

Not Just Anticoagulation—New and Old Applications of Heparin
por: Zang, Lixuan, et al.
Publicado: (2022)

Incidence and clinical relevance of heparin-induced antibodies in critically ill patients
por: Grigoriou, P, et al.
Publicado: (2004)

Perioperative statin therapy in cardiac surgery: a meta-analysis of randomized controlled trials
por: Putzu, Alessandro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v4lr1iokng4braf9pqsgbug9tk